# CSGALNACT1

## Overview
The CSGALNACT1 gene encodes the enzyme chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGalNAcT-1), which is a glycosyltransferase involved in the biosynthesis of chondroitin sulfate, a key component of the extracellular matrix. This enzyme plays a pivotal role in the initiation of chondroitin sulfate chain synthesis by transferring N-acetylgalactosamine to glucuronic acid, thus contributing to the structural integrity and function of cartilage (Gulberti2011Chondroitin; Watanabe2010Chondroitin). CSGalNAcT-1 is predominantly active in the Golgi apparatus and is crucial for normal cartilage development and chondrogenesis, particularly during early developmental stages (Sakai2007Chondroitin; Sato2003Differential). Mutations in CSGALNACT1 are associated with various congenital disorders, including skeletal dysplasia and neuropathies, underscoring its importance in both skeletal and nervous system development (Mizumoto2019CSGALNACT1‐congenital; Vodopiutz2016Chondroitin).

## Function
The CSGALNACT1 gene encodes the enzyme chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT-1), which is crucial for the biosynthesis of chondroitin sulfate (CS), a glycosaminoglycan found in the extracellular matrix. This enzyme catalyzes the transfer of N-acetylgalactosamine (GalNAc) to glucuronic acid (GlcA) on a tetrasaccharide linker, initiating the formation of CS chains (Gulberti2011Chondroitin; Watanabe2010Chondroitin). CSGalNAcT-1 is primarily responsible for the initiation of CS synthesis, a critical step that determines the type of glycosaminoglycan chain synthesized on core proteins (Sato2003Differential).

CSGalNAcT-1 is highly expressed in developing cartilage and plays a significant role in chondrogenesis during early developmental stages. Its activity is essential for normal cartilage development, as evidenced by reduced CS production and abnormal cartilage formation in CSGalNAcT1-null mice (Watanabe2010Chondroitin). The enzyme is active in the Golgi apparatus, where it facilitates the synthesis of CS chains, contributing to the structural integrity and function of cartilage by enhancing water absorption and resistance to compression (Sakai2007Chondroitin). CSGalNAcT-1's role in CS biosynthesis is crucial for maintaining the extracellular matrix and cellular signaling, impacting cell adhesion, migration, and recognition (Sato2003Differential).

## Clinical Significance
Mutations in the CSGALNACT1 gene, which encodes the enzyme chondroitin sulfate N-acetylgalactosaminyltransferase 1, are associated with several clinical conditions. These mutations can lead to congenital disorders of glycosylation, specifically a mild skeletal dysplasia characterized by advanced bone age, short stature, facial dysmorphism, and mild language delay (Mizumoto2019CSGALNACT1‐congenital). Patients with biallelic variants in CSGALNACT1 often present with skeletal abnormalities such as non-proportionate short stature, macrocephaly, brachydactyly, and scoliosis, along with neurological symptoms like ADHD (Mizumoto2019CSGALNACT1‐congenital).

In addition to skeletal dysplasia, CSGALNACT1 mutations have been linked to joint laxity and conditions resembling Desbuquois dysplasia, a chondrodysplasia with features such as micromelic short stature and brachydactyly (Vodopiutz2016Chondroitin). Mouse models with Csgalnact1-null mutations exhibit similar skeletal phenotypes, supporting the gene's role in cartilage differentiation and maturation (Vodopiutz2016Chondroitin).

Furthermore, heterozygous loss-of-function mutations in CSGALNACT1 have been associated with neuropathies, including adult-onset irreversible hemi-facial palsy and childhood-onset hereditary motor and sensory neuropathy, suggesting that altered chondroitin sulfate levels in the nervous system may contribute to these conditions (Vodopiutz2016Chondroitin).


## References


[1. (Gulberti2011Chondroitin) Sandrine Gulberti, Jean-Claude Jacquinet, Matthieu Chabel, Nick Ramalanjaona, Jacques Magdalou, Patrick Netter, Michael W H Coughtrie, Mohamed Ouzzine, and Sylvie Fournel-Gigleux. Chondroitin sulfate n-acetylgalactosaminyltransferase-1 (csgalnact-1) involved in chondroitin sulfate initiation: impact of sulfation on activity and specificity. Glycobiology, 22(4):561–571, December 2011. URL: http://dx.doi.org/10.1093/glycob/cwr172, doi:10.1093/glycob/cwr172. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/glycob/cwr172)

[2. (Watanabe2010Chondroitin) Yumi Watanabe, Kosei Takeuchi, Susumu Higa Onaga, Michiko Sato, Mika Tsujita, Manabu Abe, Rie Natsume, Minqi Li, Tatsuya Furuichi, Mika Saeki, Tomomi Izumikawa, Ayumi Hasegawa, Minesuke Yokoyama, Shiro Ikegawa, Kenji Sakimura, Norio Amizuka, Hiroshi Kitagawa, and Michihiro Igarashi. Chondroitin sulfate n-acetylgalactosaminyltransferase-1 is required for normal cartilage development. Biochemical Journal, 432(1):47–55, October 2010. URL: http://dx.doi.org/10.1042/bj20100847, doi:10.1042/bj20100847. This article has 62 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20100847)

[3. (Sakai2007Chondroitin) Kenichiro Sakai, Koji Kimata, Takashi Sato, Masanori Gotoh, Hisashi Narimatsu, Kenichi Shinomiya, and Hideto Watanabe. Chondroitin sulfate n-acetylgalactosaminyltransferase-1 plays a critical role in chondroitin sulfate synthesis in cartilage. Journal of Biological Chemistry, 282(6):4152–4161, February 2007. URL: http://dx.doi.org/10.1074/jbc.m606870200, doi:10.1074/jbc.m606870200. This article has 39 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m606870200)

[4. (Vodopiutz2016Chondroitin) Julia Vodopiutz, Shuji Mizumoto, Ekkehart Lausch, Antonio Rossi, Sheila Unger, Nikolaus Janocha, Rossella Costantini, Rainer Seidl, Susanne Greber-Platzer, Shuhei Yamada, Thomas Müller, Bernd Jilma, Rudolf Ganger, Andrea Superti-Furga, Shiro Ikegawa, Kazuyuki Sugahara, and Andreas R. Janecke. Chondroitin sulfaten-acetylgalactosaminyltransferase-1 (csgalnact-1) deficiency results in a mild skeletal dysplasia and joint laxity: human mutation. Human Mutation, 38(1):34–38, September 2016. URL: http://dx.doi.org/10.1002/humu.23070, doi:10.1002/humu.23070. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23070)

[5. (Mizumoto2019CSGALNACT1‐congenital) Shuji Mizumoto, Andreas R. Janecke, Azita Sadeghpour, Gundula Povysil, Marie T. McDonald, Sheila Unger, Susanne Greber‐Platzer, Kristen L. Deak, Nicholas Katsanis, Andrea Superti‐Furga, Kazuyuki Sugahara, Erica E. Davis, Shuhei Yamada, and Julia Vodopiutz. Csgalnact1‐congenital disorder of glycosylation: a mild skeletal dysplasia with advanced bone age. Human Mutation, 41(3):655–667, December 2019. URL: http://dx.doi.org/10.1002/humu.23952, doi:10.1002/humu.23952. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23952)

[6. (Sato2003Differential) Takashi Sato, Masanori Gotoh, Katsue Kiyohara, Tomohiro Akashima, Hiroko Iwasaki, Akihiko Kameyama, Hideo Mochizuki, Toshikazu Yada, Niro Inaba, Akira Togayachi, Takashi Kudo, Masahiro Asada, Hideto Watanabe, Toru Imamura, Koji Kimata, and Hisashi Narimatsu. Differential roles of twon-acetylgalactosaminyltransferases, csgalnact-1, and a novel enzyme, csgalnact-2. Journal of Biological Chemistry, 278(5):3063–3071, January 2003. URL: http://dx.doi.org/10.1074/jbc.m208886200, doi:10.1074/jbc.m208886200. This article has 90 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m208886200)